- Home
- LOCO vs NGNE Comparison
LOCO vs NGNE Comparison
Compare LOCO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- NGNE
- Stock Information
- Founded
- LOCO 1980
- NGNE 2003
- Country
- LOCO United States
- NGNE United States
- Employees
- LOCO N/A
- NGNE N/A
- Industry
- LOCO Restaurants
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- NGNE Health Care
- Exchange
- LOCO Nasdaq
- NGNE Nasdaq
- Market Cap
- LOCO 323.7M
- NGNE 325.3M
- IPO Year
- LOCO 2014
- NGNE N/A
- Fundamental
- Price
- LOCO $10.63
- NGNE $18.48
- Analyst Decision
- LOCO Buy
- NGNE Strong Buy
- Analyst Count
- LOCO 2
- NGNE 7
- Target Price
- LOCO $18.00
- NGNE $41.86
- AVG Volume (30 Days)
- LOCO 175.1K
- NGNE 110.1K
- Earning Date
- LOCO 10-30-2025
- NGNE 08-11-2025
- Dividend Yield
- LOCO N/A
- NGNE N/A
- EPS Growth
- LOCO N/A
- NGNE N/A
- EPS
- LOCO 0.85
- NGNE N/A
- Revenue
- LOCO $479,690,000.00
- NGNE N/A
- Revenue This Year
- LOCO $6.29
- NGNE N/A
- Revenue Next Year
- LOCO $1.56
- NGNE N/A
- P/E Ratio
- LOCO $12.53
- NGNE N/A
- Revenue Growth
- LOCO 1.85
- NGNE N/A
- 52 Week Low
- LOCO $8.29
- NGNE $6.88
- 52 Week High
- LOCO $14.10
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- LOCO 52.39
- NGNE 35.93
- Support Level
- LOCO $10.40
- NGNE $19.59
- Resistance Level
- LOCO $10.74
- NGNE $20.46
- Average True Range (ATR)
- LOCO 0.26
- NGNE 1.23
- MACD
- LOCO 0.04
- NGNE -0.20
- Stochastic Oscillator
- LOCO 75.57
- NGNE 13.37
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.